Periodontal Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Vaxcyte, AngioLab, Inc., Cortexyme, Noveome Biotherapeutics, Amyndas Pharmaceuticals, D and D Pharmatech

Periodontal Disease therapies, such as VAX PG, AL102-PDT, COR-588, ST266, AMY-101, P4M01, and others, are expected to boost the Periodontal Disease Market in the upcoming years.

DelveInsight has launched a new report on "Periodontal Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Periodontal Disease, historical and forecasted epidemiology as well as the Periodontal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Periodontal Disease market report @ https://www.delveinsight.com/report-store/periodontal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Periodontal Disease Market Report:

According to DelveInsight, the Periodontal Disease Market is projected to experience steady growth between 2023 and 2032, driven by the introduction of novel treatment options and an increasing number of diagnosed cases. Worldwide, relatively few companies are currently engaged in developing therapies for periodontal disease.
In April 2025, researchers at Penn Dental Medicine published findings on a novel therapy targeting senescent cells-aged cells that contribute to chronic inflammation. The study demonstrated that a combination of dasatinib and quercetin effectively reduced markers of senescence and periodontal inflammation in laboratory and animal models. This "senotherapy" approach offers a promising strategy for managing periodontal disease by addressing underlying cellular aging processes.
A study published in April 2025 highlighted the potential of dimethyl fumarate (DMF), an anti-inflammatory compound approved for other conditions, in preventing and alleviating periodontal tissue damage. The research indicated that DMF modulates immune responses and mitochondrial function, suggesting its utility in treating periodontal disease and other inflammation-related conditions.
In January 2024, the FDA approved a groundbreaking clinical trial led by Dr. Jonathan An at the University of Washington. This study is the first to investigate the use of rapamycin, an mTOR inhibitor known for its anti-aging properties, in treating periodontal disease among older adults. The trial aims to assess whether rapamycin can modulate immune responses and reduce inflammation in the gums, potentially altering the course of periodontal disease in individuals over 50 years old.
Key Periodontal Disease companies such as Vaxcyte, AngioLab, Inc., Cortexyme, Noveome Biotherapeutics, Amyndas Pharmaceuticals, D and D Pharmatech, and others are evaluating new drugs for Periodontal Disease to improve the treatment landscape.
Promising Periodontal Disease therapies include VAX PG, AL102-PDT, COR-588, ST266, AMY-101, P4M01, and others.

Periodontal Disease Overview

Periodontal disease, or gum disease, encompasses a range of inflammatory conditions that affect the tissues supporting and surrounding the teeth. It typically begins with bacterial buildup in the mouth, which leads to plaque formation. If plaque isn't effectively removed through daily brushing and flossing, it can harden into tartar, triggering gum inflammation (gingivitis) and potentially advancing to more serious stages of periodontal disease.

The main cause of periodontal disease is the accumulation of plaque bacteria on the teeth. Several factors increase the risk of developing the condition, including poor oral hygiene, smoking, hormonal fluctuations, certain medications, genetic factors, underlying health issues such as diabetes, and a compromised immune system.

Discover how the Periodontal Disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/periodontal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Periodontal Disease Therapy Assessment
VAX PG: Vaxcyte
AL102-PDT: AngioLab, Inc.
COR-588: Cortexyme
ST266: Noveome Biotherapeutics
AMY-101: Amyndas Pharmaceuticals
P4M01: D and D Pharmatech

Scope of the Periodontal Disease Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Periodontal Disease Companies: Vaxcyte, AngioLab, Inc., Cortexyme, Noveome Biotherapeutics, Amyndas Pharmaceuticals, D and D Pharmatech, and others
Key Periodontal Disease Therapies: VAX PG, AL102-PDT, COR-588, ST266, AMY-101, P4M01, and others
Periodontal Disease Therapeutic Assessment: Periodontal Disease current marketed and Periodontal Disease emerging therapies
Periodontal Disease Market Dynamics: Periodontal Disease market drivers and Periodontal Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Periodontal Disease Unmet Needs, KOL's views, Analyst's views, Periodontal Disease Market Access and Reimbursement

To know what's more in our Periodontal Disease report, visit https://www.delveinsight.com/report-store/periodontal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Periodontal Disease Market Report:
Periodontal Disease market report covers a descriptive overview and comprehensive insight of the Periodontal Disease Epidemiology and Periodontal Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Periodontal Disease market report provides insights into the current and emerging therapies.
The Periodontal Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Periodontal Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Periodontal Disease market.

Got queries? Click here to know more about the Periodontal Disease market Landscape https://www.delveinsight.com/sample-request/periodontal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Periodontal Disease Patient Share (%) Overview at a Glance
5. Periodontal Disease Market Overview at a Glance
6. Periodontal Disease Disease Background and Overview
7. Periodontal Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Periodontal Disease
9. Periodontal Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Periodontal Disease Emerging Therapies
12. Periodontal Disease Market Outlook
13. Country-Wise Periodontal Disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Periodontal Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Periodontal Disease Market Outlook 2034 https://www.delveinsight.com/report-store/periodontal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Periodontal Disease Pipeline Insights, DelveInsight

"Periodontal Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Periodontal Disease market. A detailed picture of the Periodontal Disease pipeline landscape is provided, which includes the disease overview and Periodontal Disease treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.